Literature DB >> 22036125

The impact of platelet membrane glycoprotein Ib alpha and Ia/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome.

Ipek Yonal1, Fehmi Hindilerden, Veysel Sabri Hancer, Bahar Artim-Esen, Aynur Daglar, Basak Akadam, Meliha Nalcaci, Reyhan Diz-Kucukkaya.   

Abstract

BACKGROUND: Pathogenesis of thrombus formation in antiphospholipid syndrome (APS) is not clear. Platelet membrane glycoprotein (GP) receptors play important roles in development of thrombosis.
OBJECTIVES: We investigated the association between development of thrombosis in APS and polymorphisms of GPIb alpha variable number of tandem repeats (VNTR), Kozak, and GPIa C807T. Patients/Methods Sixty patients with APS (30 with proven thrombosis and 30 without thrombosis) and 63 controls were included. Presence of GPIa C807T polymorphism was determined with real-time PCR and GPIb alpha Kozak and VNTR polymorphisms by conventional PCR.
RESULTS: Frequency of C807T TT genotype was significantly higher in APS with thrombosis than APS without thrombosis (p=0.023) and also in APS with multiple thrombi compared to APS without thrombi (p=0.023). Frequency of Kozak TC genotype was higher in APS with arterial thrombosis compared to APS with venous thrombosis, controls, and APS without thrombosis (p=0.03, p=0.0007, and p=0.0024 respectively). D allele frequency and D allele carrier state for VNTR were significantly less in APS than controls (p=0.0018 and p=0.0046 respectively).
CONCLUSIONS: C807T TT genotype may confer a risk for thrombosis and Kozak TC genotype for arterial thrombosis. D allele of VNTR may protect from APS. No patients with C807T TT or Kozak TC genotypes carried the protective DD genotype of VNTR. These polymorphisms may increase risk for both arterial and venous thrombosis. The utility of prophylaxis with anti-platelet drugs in at least a subgroup of APS patients should be investigated with clinical trials.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22036125     DOI: 10.1016/j.thromres.2011.10.005

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  Genetics of Antiphospholipid Syndrome.

Authors:  Lourdes Ortiz-Fernández; Amr H Sawalha
Journal:  Curr Rheumatol Rep       Date:  2019-12-05       Impact factor: 4.592

Review 2.  Thrombotic risk in antiphospholipidic syndrome: From hypothesis to current evidence (Review).

Authors:  Claudia Mihaela Gavriș; Laurențiu Dănuț Nedelcu; Alina Mihaela Pascu
Journal:  Exp Ther Med       Date:  2021-01-26       Impact factor: 2.447

3.  Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non BCR-ABL Myeloproliferative Neoplasms: A Pilot Study.

Authors:  R Dambrauskienė; R Gerbutavičius; R Ugenskienė; R Jankauskaitė; A Savukaitytė; R Šimoliūnienė; M Rudžianskienė; R Gerbutavičienė; E Juozaitytė
Journal:  Balkan J Med Genet       Date:  2017-06-30       Impact factor: 0.519

Review 4.  New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches.

Authors:  Chary Lopez-Pedrera; Nuria Barbarroja; Alejandra Mª Patiño-Trives; Eduardo Collantes; Mª Angeles Aguirre; Carlos Perez-Sanchez
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561

5.  Predictive Value of Kozak Gene Polymorphism for Thrombosis in Patients with Philadelphia-Negative MPNs.

Authors:  Mohammed Sabry El-Ghonemy; Shaimaa El-Ashwah; May Denewer; Eman Adel Soliman; Mohammed El-Baiomy; Heidi Elkerdawy; Ahmed El-Sebaie
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.